Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 3
Submit an article Journal homepage
261
Views
22
CrossRef citations to date
0
Altmetric
Review

Identifying determinants of variability to tailor aspirin therapy

Bianca Rocca Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. [email protected]; Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. [email protected]
,
Alfredo Dragani Department of Hematology, Spirito Santo Hospital, Pescara, Italy; Department of Hematology, Spirito Santo Hospital, Pescara, Italy
&
Francesca Pagliaccia Department of Pharmacology, Catholic University School of Medicine, Rome, Italy; Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
Pages 365-379 | Published online: 10 Jan 2014

References

  • Buxton ILO. Pharmacokinetics and Pharmacodynamics. In: Goodman & Gilman. The Pharmacological Basis of Therapeutics (11th Edition). Brunton LL (Ed.). McGraw-Hill, New York, NY, USA, 1–39 (2005).
  • Gumbo T. General Principle of antimicrobial therapy. In: Goodman & Gilman. The Pharmacological Basis of Therapeutics (12th Edition). Bruton LL (Ed.). McGraw-Hill, New York, NY, USA, 1365–1381 (2011).
  • Shuen AY, Wong BY, Fu L, Selby R, Cole DE. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Clin. Biochem. 45(6), 397–401 (2012).
  • Patrono C, Rocca B. Drug insight: aspirin resistance – fact or fashion? Nat. Clin. Pract. Cardiovasc. Med. 4(1), 42–50 (2007).
  • Hjemdahl P. Aspirin resistance testing not ready for ‘prime time’. Heart 95(15), 1220–1222 (2009).
  • Santilli F, Rocca B, De Cristofaro R et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin ‘resistance’. J. Am. Coll. Cardiol. 53(8), 667–677 (2009).
  • Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J. Thromb. Haemost. 7(6), 1029 (2009).
  • Gorog DA, Sweeny JM, Fuster V. Antiplatelet drug ‘resistance’. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat. Rev. Cardiol. 6(5), 365–373 (2009).
  • Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler. Thromb. Vasc. Biol. 28(3), s25–s32 (2008).
  • Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J. 28(14), 1702–1708 (2007).
  • Lordkipanidzé M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease. Am. J. Cardiol. 104(9), 1189–1193 (2009).
  • Blais N, Pharand C, Lordkipanidzé M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb. Haemost. 102(2), 404–411 (2009).
  • Michelson AD, Cattaneo M, Eikelboom JW et al.; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost. 3(6), 1309–1311 (2005).
  • Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation 110(12), 1706–1708 (2004).
  • Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb. Haemost. 101(2), 333–339 (2009).
  • Muir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 95(15), 1225–1229 (2009).
  • Linnemann B, Prochnow S, Mani H, Schwonberg J, Lindhoff-Last E. Variability of nonresponse to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. Ann. Hematol. 88(10), 979–988 (2009).
  • Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167(15), 1593–1599 (2007).
  • Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am. Heart J. 153(2), 175–181 (2007).
  • Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336(7637), 195–198 (2008).
  • Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71–86 (2002).
  • Becker RC, Meade TW, Berger PB et al.; American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl.), 776S–814S (2008).
  • Price MJ, Berger PB, Teirstein PS et al.; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11), 1097–1105 (2011).
  • Campbell CL, Steinhubl SR. Variability in response to aspirin: do we understand the clinical relevance? J. Thromb. Haemost. 3(4), 665–669 (2005).
  • Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J. Thromb. Haemost. 3(8), 1597–1602 (2005).
  • Myers RI. The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials. Proc. (Bayl. Univ. Med. Cent.) 18(4), 331–336 (2005).
  • De Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? J. Thromb. Haemost. 1(9), 2048–2050 (2003).
  • Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J. Clin. Invest. 47(9), 2169–2180 (1968).
  • O’Brien JR. Effect of salicylates on human platelets. Lancet 1(7557), 1431 (1968).
  • Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194, 927–929 (1962).
  • Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc. Natl Acad. Sci. USA 72(8), 3073–3076 (1975).
  • Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol. 231(25), 235–237 (1971).
  • Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl Acad. Sci. USA 72(8), 2994–2998 (1975).
  • Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J. Clin. Invest. 61(2), 314–319 (1978).
  • Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J. Clin. Invest. 56(3), 624–632 (1975).
  • Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. 2(8), 637–643 (1995).
  • Patrono C, Rocca B. Aspirin, 110 years later. J. Thromb. Haemost. 7(Suppl. 1), 258–261 (2009).
  • Patrono C, Ciabattoni G, Patrignani P et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72(6), 1177–1184 (1985).
  • FitzGerald GA, Brash AR, Oates JA, Pedersen AK. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J. Clin. Invest. 72(4), 1336–1343 (1983).
  • Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 311(19), 1206–1211 (1984).
  • de Gaetano G, Cerletti C, Dejana E, Latini R. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation 72(6), 1185–1193 (1985).
  • Patrono C, Ciabattoni G, Pinca E et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res. 17(3–4), 317–327 (1980).
  • Hamberg M, Svensson J, Samuelsson B. Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc. Natl Acad. Sci. USA 71(10), 3824–3828 (1974).
  • Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69(1), 180–186 (1987).
  • Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69(6), 1366–1372 (1982).
  • Siebert DJ, Bochner F, Imhoff DM et al. Aspirin kinetics and platelet aggregation in man. Clin. Pharmacol. Ther. 33(3), 367–374 (1983).
  • Cerletti C, Latini R, Dejana E, Tognoni G, Garattini S, de Gaetano G. Inhibition of human platelet thromboxane generation by aspirin in the absence of measurable drug levels in peripheral blood. Biochem. Pharmacol. 34(10), 1839–1841 (1985).
  • Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA. Protein synthesis by platelets: historical and new perspectives. J. Thromb. Haemost. 7(2), 241–246 (2009).
  • Italiano JE Jr, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J. Cell Biol. 147(6), 1299–1312 (1999).
  • Rao GH, Johnson GJ, Reddy RK, White JG. Rapid return of cyclooxygenase active platelets in dogs after a single oral dose of aspirin. Prostaglandins 22(5), 761–772 (1981).
  • Worthington RE, Nakeff A. Aspirin inhibits rat megakaryocyte thromboxane synthesis. Prostaglandins 23(6), 841–853 (1982).
  • Dejana E, Barbieri B, Cerletti C, Livio M, de Gaetano G. Impaired thromboxane production by newly formed platelets after aspirin administration to thrombocytopenic rats. Br. J. Haematol. 46(3), 465–469 (1980).
  • Haeggström JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem. Rev. 111(10), 5866–5898 (2011).
  • Siegel MI, McConnell RT, Cuatrecasas P. Aspirin-like drugs interfere with arachidonate metabolism by inhibition of the 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway. Proc. Natl Acad. Sci. USA 76(8), 3774–3778 (1979).
  • Tremoli E, Maderna P, Eynard A, Gregori M, Galli G. In vitro effects of aspirin and non steroidal anti-inflammatory drugs on the formation of 12-hydroxyeicosatetraenoic acid by platelets. Prostaglandins Leukot. Med. 23(2–3), 117–122 (1986).
  • Eynard AR, Galli G, Tremoli E, Maderna P, Magni F, Paoletti R. Aspirin inhibits platelet 12-hydroxy-eicosatetraenoic acid formation. J. Lab. Clin. Med. 107(1), 73–78 (1986).
  • Radomski M, Michalska Z, Marcinkiewicz E, Gryglewski RJ. Salicylates and 12-lipoxygenase activity in human washed platelets. Pharmacol. Res. Commun. 18(11), 1015–1030 (1986).
  • Maderna P, Caruso D, Tremoli E, Galli G. Differential effects of oral administrations to human volunteers of acetylsalicylic acid, sodium salicylate and indomethacin on 12-hydroxyeicosatetraenoic acid formation by stimulated platelets. Thromb. Res. 52(3), 197–206 (1988).
  • Holinstat M, Boutaud O, Apopa PL et al. Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2a differently for cyclooxygenase-1 and 12-lipoxygenase catalysis. Arterioscler. Thromb. Vasc. Biol. 31(2), 435–442 (2011).
  • Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can. J. Cardiol. 11(3), 221–227 (1995).
  • Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev. Cardiovasc. Ther. 5(1), 45–55 (2007).
  • Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J. Pharm. Sci. 61(3), 379–385 (1972).
  • Levy G. Pharmacokinetics of salicylate in man. Drug Metab. Rev. 9(1), 3–19 (1979).
  • Tang M, Mukundan M, Yang J et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther. 319(3), 1467–1476 (2006).
  • Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, Yan B. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem. Pharmacol. 77(2), 238–247 (2009).
  • Williams FM. Clinical significance of esterases in man. Clin. Pharmacokinet. 10(5), 392–403 (1985).
  • Rylance HJ, Wallace RC. Erythrocyte and plasma aspirin esterase. Br. J. Clin. Pharmacol. 12(3), 436–438 (1981).
  • Zhou G, Marathe GK, Willard B, McIntyre TM. Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. J. Biol. Chem. 286(40), 34820–34829 (2011).
  • Zavodnik IB, Lapshina E, Sudnikovich E et al. Structure, stability, and antiplatelet activity of O-acyl derivatives of salicylic acid and lipophilic esters of acetylsalicylate. Pharmacol. Rep. 61(3), 476–489 (2009).
  • Rosenkranz B, Fischer C, Meese CO, Frölich JC. Effects of salicylic and acetylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man. Br. J. Clin. Pharmacol. 21(3), 309–317 (1986).
  • Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur. J. Clin. Pharmacol. 35(3), 287–294 (1988).
  • de la Cruz JP, Guerrero A, González-Correa JA, Márquez E, Nacle I, Sánchez de la Cuesta F. Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans. Eur. J. Clin. Pharmacol. 57(11), 775–780 (2002).
  • Ali M, McDonald JW, Thiessen JJ, Coates PE. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 11(1), 9–13 (1980).
  • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2(8607), 349–360 (1988).
  • Patrono C, Andreotti F, Arnesen H et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur. Heart J. 32(23), 2922–2932 (2011).
  • Mehta SR, Bassand JP, Chrolavicius S et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N. Engl. J. Med. 363(10), 930–942 (2010).
  • Kushner FG, Hand M, Smith SC Jr et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120(22), 2271–2306 (2009).
  • Anderson JL, Adams CD, Antman EM et al.; 2011 Writing group members; ACCF/AHA Task Force members. 2011 ACCF/AHA Focused Update Incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123(18), e426–e579 (2011).
  • Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e89S–e119S (2012).
  • Lordkipanidzé M, Harrison P. Aspirin twice a day keeps new COX-1 at bay. J. Thromb. Haemost. 10(7), 1217–1219 (2012).
  • Peace A, McCall M, Tedesco T et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J. Thromb. Haemost. 8(10), 2323–2325 (2010).
  • Maree AO, Curtin RJ, Dooley M et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J. Am. Coll. Cardiol. 46(7), 1258–1263 (2005).
  • Tefferi A. Overcoming ‘aspirin resistance’ in MPN. Blood 119(15), 3377–3378 (2012).
  • Granger BB, Swedberg K, Ekman I et al.; CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366(9502), 2005–2011 (2005).
  • Hennekens CH, Schneider WR, Hebert PR, Tantry US, Gurbel PA. Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to ‘aspirin resistance’. Am. Heart J. 159(5), 744–748 (2010).
  • Dawson J, Quinn T, Rafferty M et al. Aspirin resistance and compliance with therapy. Cardiovasc. Ther. 29(5), 301–307 (2011).
  • Cuisset T, Frere C, Quilici J et al. Aspirin noncompliance is the major cause of ‘aspirin resistance’ in patients undergoing coronary stenting. Am. Heart J. 157(5), 889–893 (2009).
  • Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 3(4), 383–388 (1983).
  • Peterson DA, Gerrard JM, Rao GH, White JG. Salicylic acid inhibition of the irreversible effect of acetylsalicyclic aicd on prostaglandin synthetase may be due to competition for the enzyme cationic binding site. Prostaglandins Med. 6(2), 161–164 (1981).
  • Ali M, McDonald JW. Interference by sulfinpyrazone and salicylate of aspirin inhibition of platelet cyclooxygenase activity. Prostaglandins Med. 3(6), 327–332 (1979).
  • Merino J, Livio M, Rajtar G, de Gaetano G. Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation. Biochem. Pharmacol. 29(8), 1093–1096 (1980).
  • Cerletti C, Livio M, De Gaetano G. Nonsteroidal anti-inflammatory drugs react with two sites on platelet cyclooxygenase. Evidence from ‘in vivo’ drug interaction studies in rats. Biochim. Biophys. Acta 714(1), 122–128 (1982).
  • Livio M, Del Maschio A, Cerletti C, de Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclooxygenase activity. Prostaglandins 23(6), 787–796 (1982).
  • Rajtar G, Cerletti C, Livio M, de Gaetano G. Sulphinpyrazone prevents in vivo the inhibitory effect of aspirin on rat platelet cyclooxygenase activity. Biochem. Pharmacol. 30(20), 2773–2776 (1981).
  • Vargaftig BB. The inhibition of cyclooxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines. Eur. J. Pharmacol. 50(3), 231–241 (1978).
  • Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345(25), 1809–1817 (2001).
  • FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 361(9357), 542–544 (2003).
  • Abraham NS, Hlatky MA, Antman EM et al.; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton-pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 122(24), 2619–2633 (2010).
  • Ljung R, Lu Y, Lagergren J. High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study. Drugs Aging 28(6), 469–476 (2011).
  • Adams RJ, Appleton SL, Gill TK, Taylor AW, Wilson DH, Hill CL. Cause for concern in the use of nonsteroidal anti-inflammatory medications in the community – a population-based study. BMC Fam. Pract. 12, 70 (2011).
  • Charlot M, Grove EL, Hansen PR et al. Proton-pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 342, d2690 (2011).
  • Gurbel PA, Tantry US. Antiplatelet therapy: Clopidogrel–PPI interaction, an ongoing controversy. Nat. Rev. Cardiol. 8(1), 7–8 (2011).
  • Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat. Rev. Cardiol. 8(10), 560–571 (2011).
  • Voora D, Horton J, Shah SH, Shaw LK, Newby LK. Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. Am. Heart J. 162(1), 166–172.e1 (2011).
  • Lordkipanidzé M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb. Res. 128(1), 47–53 (2011).
  • Jefferson BK, Foster JH, McCarthy JJ et al. Aspirin resistance and a single gene. Am. J. Cardiol. 95(6), 805–808 (2005).
  • Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb. Res. 119(3), 355–360 (2007).
  • Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 104(23), 2855–2864 (2001).
  • McGorrian C, Yusuf S, Islam S et al.; INTERHEART Investigators. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur. Heart J. 32(5), 581–589 (2011).
  • Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41(12), 913–958 (2002).
  • Graham DY, Smith JL. Aspirin and the stomach. Ann. Intern. Med. 104(3), 390–398 (1986).
  • de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin. Pharmacol. 1, 1 (2001).
  • Hirata Y, Kataoka H, Shimura T et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand. J. Gastroenterol. 46(7–8), 803–809 (2011).
  • Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348(9039), 1413–1416 (1996).
  • Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37(8), 2153–2158 (2006).
  • Cerletti C, Dell’Elba G, Manarini S et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin. Pharmacokinet. 42(12), 1059–1070 (2003).
  • Latini R, Cerletti C, de Gaetano G et al. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations. Int. J. Clin. Pharmacol. Ther. Toxicol. 24(6), 313–318 (1986).
  • Bochner F, Somogyi AA, Wilson KM. Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. Clin. Pharmacokinet. 21(5), 394–399 (1991).
  • Poirier P, Giles TD, Bray GA et al.; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113(6), 898–918 (2006).
  • Whitlock G, Lewington S, Sherliker P et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 373(9669), 1083–1096 (2009).
  • Jain R, Chung SM, Jain L et al. Implications of obesity for drug therapy: limitations and challenges. Clin. Pharmacol. Ther. 90(1), 77–89 (2011).
  • Jernås M, Olsson B, Arner P et al. Regulation of carboxylesterase 1 (CES1) in human adipose tissue. Biochem. Biophys. Res. Commun. 383(1), 63–67 (2009).
  • Chemoyl G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin. Pharmacokinet. 39(3), 215–231 (2000).
  • Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 49(2), 71–87 (2010).
  • Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br. J. Haematol. 155(2), 137–149 (2011).
  • Drazin D, Choulakian A, Nuño M, Kornbluth P, Alexander MJ. Bodyweight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. J. Neurointerv. Surg. 3(2), 177–181 (2011).
  • Bordeaux BC, Qayyum R, Yanek LR et al. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev. Cardiol. 13(2), 56–62 (2010).
  • Rocca B, Santilli F, Pitocco D et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J. Thromb. Haemost. 10(7), 1220–1230 (2012).
  • Fontana P, Berdagué P, Castelli C et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J. Thromb. Haemost. 8(12), 2614–2623 (2010).
  • Sarno G, Garg S, Onuma Y et al. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). Am. J. Cardiol. 105(4), 475–479 (2010).
  • Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678), 1849–1860 (2009).
  • McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol. Rev. 56(2), 163–184 (2004).
  • Hines LE, Murphy JE. Potentially harmful drug–drug interactions in the elderly: a review. Am. J. Geriatr. Pharmacother. 9(6), 364–377 (2011).
  • Trifirò G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr. Drug Metab. 12(7), 611–620 (2011).
  • Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J. Thromb. Haemost. 8(10), 2105–2112 (2010).
  • Franchini M. Hemostasis and aging. Crit. Rev. Oncol. Hematol. 60(2), 144–151 (2006).
  • Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353(22), 2373–2383 (2005).
  • Hubbard RE, O’Mahony MS, Calver BL, Woodhouse KW. Plasma esterases and inflammation in ageing and frailty. Eur. J. Clin. Pharmacol. 64(9), 895–900 (2008).
  • Segal JB, Moliterno AR. Platelet counts differ by sex, ethnicity, and age in the United States. Ann. Epidemiol. 16(2), 123–130 (2006).
  • Pascale S, Petrucci G, Dragani A et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 119(15), 3595–3603 (2012).
  • Teramoto T, Shimada K, Uchiyama S et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP) – a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am. Heart J. 159(3), 361–369.e4 (2010).
  • Guthikonda S, Lev EI, Patel R et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J. Thromb. Haemost. 5(3), 490–496 (2007).
  • Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87(3), 285–293 (2012).
  • Gruppo Italiano Studio Policitemia (GISP). Low-dose aspirin in polycythaemia vera: a pilot study. Br. J. Haematol. 97(2), 453–456 (1997).
  • Rocca B, Ciabattoni G, Tartaglione R et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb. Haemost. 74(5), 1225–1230 (1995).
  • Dragani A, Pascale S, Recchiuti A et al. The contribution of cyclooxygenase-1 and-2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 115(5), 1054–1061 (2010).
  • Würtz M, Grove EL, Wulff LN et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc. Interv. 3(8), 828–835 (2010).
  • Zanazzi M, Cesari F, Rosso G et al. Reticulated platelets and platelet reactivity in renal transplant recipients receiving antiplatelet therapy. Transplant. Proc. 42(4), 1156–1157 (2010).
  • Dillinger JG, Sideris G, Henry P, Bal dit Sollier C, Ronez E, Drouet L. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb. Res. 129(1), 91–94 (2012).
  • De Berardis G, Sacco M, Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 339, b4531 (2009).
  • Price HC, Holman RR. Primary prevention of cardiovascular events in diabetes: is there a role for aspirin? Nat. Clin. Pract. Cardiovasc. Med. 6(3), 168–169 (2009).
  • Belch J, MacCuish A, Campbell I et al.; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337, a1840 (2008).
  • Ogawa H, Nakayama M, Morimoto T et al.; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with Type 2 diabetes: a randomized controlled trial. JAMA 300(18), 2134–2141 (2008).
  • DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56(12), 3014–3019 (2007).
  • Evangelista V, de Berardis G, Totani L et al. Persistent platelet activation in patients with Type 2 diabetes treated with low doses of aspirin. J. Thromb. Haemost. 5(11), 2197–2203 (2007).
  • El Haouari M, Rosado JA. Platelet signalling abnormalities in patients with Type 2 diabetes mellitus: a review. Blood Cells Mol. Dis. 41(1), 119–123 (2008).
  • Di Minno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68(4), 886–891 (1986).
  • Di Minno G. Aspirin resistance and platelet turnover: a 25-year old issue. Nutr. Metab. Cardiovasc. Dis. 21(8), 542–545 (2011).
  • Brown AS, Hong Y, de Belder A et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17(4), 802–807 (1997).
  • Rao AK, Goldberg RE, Walsh PN. Platelet coagulant activities in diabetes mellitus. Evidence for relationship between platelet coagulant hyperactivity and platelet volume. J. Lab. Clin. Med. 103(1), 82–92 (1984).
  • Tschöpe D, Schwippert B, Schettler B et al. Increased GPIIB/IIIA expression and altered DNA-ploidy pattern in megakaryocytes of diabetic BB-rats. Eur. J. Clin. Invest. 22(9), 591–598 (1992).
  • Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 61(6), 1081–1085 (1983).
  • Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J. Thromb. Haemost. 9(1), 185–191 (2011).
  • Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with Type 2 diabetes mellitus and micro- or macro-vascular complications. Thromb. Haemost. 106(3), 491–499 (2011).
  • Bala M, Chin CN, Logan AT et al. Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem. Pharmacol. 75(7), 1472–1481 (2008).
  • Lordkipanidzé M, Diodati JG, Turgeon J, Schampaert E, Palisaitis DA, Pharand C. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. Int. J. Cardiol. 143(1), 43–50 (2010).
  • Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int. J. Cardiol. 150(1), 39–44 (2011).
  • Henry P, Vermillet A, Boval B et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb. Haemost. 105(2), 336–344 (2011).
  • Addad F, Chakroun T, Elalamy I et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int. J. Hematol. 92(2), 296–301 (2010).
  • Capodanno D, Patel A, Dharmashankar K et al. Pharmacodynamic effects of different aspirin dosing regimens in Type 2 diabetes mellitus patients with coronary artery disease. Circ. Cardiovasc. Interv. 4(2), 180–187 (2011).
  • Abe Y, Wada H, Tomatsu H et al. A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF). Thromb. Res. 118(4), 463–469 (2006).
  • Lev EI, Solodky A, Harel N et al. Treatment of aspirin-resistant patients with ω-3 fatty acids versus aspirin dose escalation. J. Am. Coll. Cardiol. 55(2), 114–121 (2010).
  • Rocca B, Petrucci G. Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis 2012, 376721 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.